Objective To investigate the clinical effect of pirfenidone combined with prednisone acetate in the treatment of idiopathic pulmonary fibrosis（IPF）. Methods Sixty-six patients with IPF admitted to a hospital in Dalian from January 2018 to March 2021 were selected for the study.A random number table was used to divide the patients into a study group and a control group

with 33 cases in each group.Patients in the control group were treated with prednisone acetate

while patients in the study group were treated with pirfenidone combination therapy based on the control group.The forced expiratory volume in 1 second（FEV1）

maximal voluntary ventilation（MVV）

and peak expiratory flow（PEF） were compared between the 2 groups before and after treatment.The levels of tumor necrosis factor-α（TNF-α）

interleukin-6（IL-6）

and immunoglobulin E（Ig E） were compared between the 2 groups before and after treatment. The occurrence of adverse reactions was compared between the 2 groups after drug administration. Results Before treatment

there was no statistically significant difference between the FEV1

MVV

and PEF levels in the 2 groups（P >0.05）. After treatment

the levels of FEV1

MVV

and PEF in the 2 groups were higher than those before treatment

and higher in the study group than in the control group

with statistically significant differences（P<0.05）. Before treatment

the levels of TNF-α

IL-6

and Ig E in the 2 groups were compared

and the differences were not statistically significant（P >0.05）. After treatment

the levels of TNF-α

IL-6

and Ig E in the 2 groups were lower than before treatment

and the figures for the study group were lower than those for the control group. The differences were all statistically significant（P<0.05）. The difference was not statistically significant（P>0.05） when comparing the incidence of adverse reactions in the 2 groups. Conclusion The clinical effect of pirfenidone combined with prednisone acetate in the treatment of IPF is significant

and it can effectively improve the lung function and TNF-α

IL-6

and Ig E levels of patients while showing a high safety profile. Therefore

it holds considerable clinical value.